Related by context. All words. (Click for frequent words.) 74 relapsed MM 74 NNRTI resistance 73 protease inhibitor PI 73 trastuzumab Herceptin ® 72 K ras mutations 72 ritonavir boosted 72 abacavir lamivudine 72 virologic failure 71 K#N 71 viral kinetics 71 virological response 71 HBeAg negative 70 virologic responses 70 sustained virological response 70 HER2 overexpression 70 clevidipine 70 recurrent glioblastoma multiforme 70 Subgroup analyzes 70 ribavirin therapy 70 caspofungin 70 NRTI resistance 70 pentoxifylline 70 APTIVUS r 70 virological failure 70 undetectable HBV DNA 70 HER2 expression 70 Subgroup analysis 70 AZT zidovudine Retrovir 70 virologic breakthrough 69 antiretroviral naïve 69 PEG IFN 69 tipranavir r 69 rFSH 69 HBsAg 69 NRTI 69 liver histology 69 interferon ribavirin 69 stavudine d4T 69 flutamide 69 virologically 69 HBeAg negative patients 69 tipranavir ritonavir 69 ß blockers 69 abacavir Ziagen 69 MAGE A3 ASCI 69 postoperative chemotherapy 69 galiximab 69 poor metabolizers 69 CIMZIA TM certolizumab pegol 69 β blockers 69 dosage regimens 68 HIV RNA 68 seropositivity 68 dalteparin 68 tumor histology 68 lenalidomide dexamethasone 68 Pharmacokinetics PK 68 ancrod 68 ethambutol 68 certolizumab 68 fluvastatin 68 plasma pharmacokinetics 68 nelfinavir 68 doxorubicin docetaxel 68 pharmacodynamic parameters 68 BEXXAR Therapeutic Regimen 68 taxane resistant 68 EGFR TKI 68 tumor necrosis 68 ritonavir boosted protease inhibitor 68 gemcitabine carboplatin 68 complete cytogenetic response 68 sustained virologic response 68 virologic 68 PREZISTA r 68 virologic response 68 overt nephropathy 68 NNRTIs 68 posaconazole 68 CsA 68 baseline LDH 68 mg kg dose 68 pegylated liposomal doxorubicin 68 pCR 68 tipranavir 68 indinavir 68 HBeAg 68 inotropic 68 micafungin 68 CCyR 68 bovine thrombin 68 darunavir ritonavir 68 CIMZIA ™ 68 corifollitropin alfa 68 nonnucleoside reverse transcriptase inhibitors 68 CANCIDAS 68 Triapine R 68 BCR ABL mutations 68 nonrandomized 68 lamivudine resistant 68 enfuvirtide 68 ALT flares 68 ribavirin RBV 68 hepatic fibrosis 68 ABCB1 68 inhibitor RG# 68 NMIBC 67 pyrazinamide 67 biochemical relapse 67 postintervention 67 colorectal adenoma 67 Immunohistochemical analysis 67 KRAS status 67 HCV replicon 67 metastatic neuroendocrine tumors 67 receptor tyrosine kinase inhibitor 67 paricalcitol 67 amoxicillin clavulanate 67 crizotinib PF # 67 posttreatment 67 immunomodulatory therapy 67 mycophenolate mofetil 67 epoetin beta 67 CIN2 + 67 timepoints 67 antiretroviral naive 67 DAS# CRP 67 ertapenem 67 Cardiotoxicity 67 riociguat 67 -#.# log# 67 atazanavir ritonavir 67 TURBT 67 lumiliximab 67 MYCAMINE 67 mRCC 67 CYP#D# inhibitor 67 APTIVUS R 67 genotypic 67 HBeAg positive 67 radezolid 67 APTIVUS 67 HBeAg seroconversion 67 histological subtype 67 RRMS patients 67 pharmacokinetic interactions 67 multivariate analyzes 67 QTc prolongation 67 nucleoside analogues 67 imatinib resistance 67 BARACLUDE ® 67 FOLFOX6 67 chemotherapy cisplatin 67 cranial irradiation 67 Gag polymorphisms 67 concurrent chemoradiation 67 antiandrogen 67 AST ALT 67 completely resected 67 bladder carcinoma 67 TKI therapy 67 TDF FTC 67 nadolol 67 monoinfected patients 67 DAPT 67 Secondary efficacy endpoints 67 Primary endpoints 67 coinfected patients 67 interferon alfa 2b 67 NRTI backbone 67 mg/m2 dose 67 NNRTI resistant virus 67 nicardipine 67 alkylating agent 67 prospectively defined 67 ara C 67 piperacillin tazobactam 67 liver biopsies 67 S/GSK# 66 antidiabetic medications 66 Viral load 66 HAART regimens 66 sargramostim 66 vicriviroc 66 CCR5 antagonist 66 aldosterone antagonist 66 tigecycline 66 PegIFN RBV 66 definite stent thrombosis 66 weekly subcutaneous injections 66 efavirenz EFV 66 antibody titer 66 desvenlafaxine succinate 66 TPV r 66 RhuDex TM 66 debulking surgery 66 CCR5 inhibitor 66 seronegative 66 UGT#A# * 66 Kaplan Meier analysis 66 imatinib therapy 66 thalidomide Thalomid 66 Xelox 66 pamidronate 66 histologically proven 66 liver transplant recipients 66 antiandrogens 66 locoregional recurrence 66 anagrelide 66 alvespimycin 66 detectable HCV RNA 66 tropism testing 66 receptor inhibitor 66 antiviral efficacy 66 retrospective cohort 66 q8h 66 methotrexate monotherapy 66 dose cohort 66 HCV SPRINT 66 HSCT 66 LPV r 66 ceftazidime 66 TMC# r 66 CR nPR 66 comparator arm 66 forodesine 66 serum phosphorous 66 gastric adenocarcinoma 66 KRAS mutations occur 66 amisulpride 66 Cloretazine 66 adefovir 66 heavily pretreated 66 microsatellite instability 66 pharmacokinetics PK 66 oral FTY# 66 hematopoietic cancers 66 selective modulator 66 bezafibrate 66 KRAS mutant tumors 66 rifabutin 66 thrombocytopenic 66 cART 66 pomalidomide 66 potent antiretroviral therapy 66 serum HCV RNA 66 Virologic 66 morphometric vertebral fractures 66 randomized multicenter trial 66 liver metastasis 66 fosbretabulin 66 busulfan 66 stage IIIb IV 66 boosted protease inhibitor 66 haematologic 66 abnormal cytology 66 clodronate 66 ug dose 66 Vidaza azacitidine 66 prognostic indicators 66 iniparib 66 electrophysiologic 66 papillary renal cell carcinoma 66 spirometric 66 saquinavir ritonavir 66 atorvastatin #mg 66 nab paclitaxel 66 CCR5 tropic HIV 66 lipid lowering agents 66 ADAGIO study 66 operable breast cancer 66 FOLPI 66 preoperative chemotherapy 66 IFN α 66 eculizumab therapy 66 NATRECOR ® 66 VFEND 66 methotrexate therapy 66 protease inhibitors PIs 66 pharmacokinetic parameters 66 metastatic malignant 66 Genotypic 66 hematological parameters 66 lopinavir 66 prostate cancer CaP 66 BRAF V#E mutation 65 HIV coinfected 65 aromatase inhibitor therapy 65 MMSE score 65 adenoma recurrence 65 intravenous cyclophosphamide 65 treatment naive genotype 65 epithelial tumors 65 Kinoid 65 bronchoalveolar lavage 65 cisplatin gemcitabine 65 fosamprenavir 65 pharmacodynamic markers 65 serum HBV DNA 65 anthracycline taxane 65 3TC lamivudine Epivir 65 ritonavir boosted lopinavir 65 Doxil ® 65 neurologic progression 65 pharmacologic stress 65 IL#B 65 edifoligide 65 SPRYCEL ® 65 VELCADE melphalan 65 CYT# potent vascular disrupting 65 ZOLINZA 65 erythropoietic 65 metastatic RCC 65 clomipramine 65 pharmacodynamic properties 65 HCV genotype 65 Non inferiority 65 nucleoside reverse transcriptase inhibitor 65 inflammatory biomarkers 65 chemoradiation therapy 65 cis retinoic acid 65 mCRC patients 65 darunavir 65 INTELENCE 65 AGILECT R 65 Tasigna prolongs 65 antithymocyte globulin 65 griseofulvin 65 % CI #.#-#.# [003] 65 biliary tract cancer 65 ovarian carcinoma 65 erlotinib Tarceva ® 65 sorafenib tablets 65 anti leukemic 65 divalproex sodium 65 CC genotype 65 adjuvant cisplatin 65 phase IIIb 65 darunavir r 65 adalimumab Humira 65 HAART regimen 65 moderately emetogenic 65 NNT = 65 pharmacodynamics PD 65 dose proportionality 65 elotuzumab 65 HBeAg positive patients 65 CDK inhibitor 65 humanised monoclonal antibody 65 nonmetastatic 65 M#V mutation 65 DEB# 65 Cytoxan 65 Pharmacokinetic parameters 65 ZACTIMA 65 hematologic toxicity 65 PSA nadir 65 F FDG PET 65 mcg doses 65 nucleoside analog 65 docetaxel chemotherapy 65 dasatinib Sprycel 65 FluCAM arm 65 pegylated interferon alfa 65 sotalol 65 sorafenib Nexavar 65 logistic regression models 65 noninferiority 65 miconazole Lauriad ® 65 Multivariate logistic regression 65 multivariable analysis 65 d4T stavudine Zerit 65 MVA MUC1 IL2 65 #mg QD [001] 65 oral antifungal 65 dose escalation phase 65 antiangiogenic therapy 65 cinacalcet 65 T#I [002] 65 HBV DNA 65 vidofludimus 65 lupus anticoagulant 65 p# biomarker 65 tipifarnib 65 nucleoside naive 65 AGHD 65 therapeutic regimens 65 mcg albinterferon alfa 2b 65 histologic subtype 65 Velcade bortezomib 65 bendamustine 65 antitumor effect 65 duplex ultrasonography 65 postmenopausal osteoporotic women 65 Hepsera adefovir dipivoxil 65 budesonide foam 65 taxane chemotherapy 65 rifamycins 65 pT3 65 elevated ALT 65 postoperative complication 65 HER2 amplification 65 teriflunomide 65 ENMD # 65 irbesartan 65 Pharmacokinetic studies 65 DMARD 65 orally administered inhibitor 65 stage IIIB 65 gemcitabine Gemzar 65 pharmacologically active isomer 65 microbiological eradication 65 estramustine 65 mitoxantrone plus 65 concomitant medications 65 GAMMAGARD 65 octreotide LAR 65 peginterferon alfa 2b 65 NRTIs 65 nevirapine Viramune 65 virologic suppression 65 rapid virologic response 65 antiviral prophylaxis 65 BENICAR HCT 65 dosing cohort 65 mitochondrial toxicity 65 pyrimethamine 65 peginterferon alfa 65 imipenem 65 INTERCEPT platelets 65 fluoropyrimidine 65 #mg dose [002] 65 IGRAs 65 trimethoprim sulfamethoxazole 65 endoscopic remission 65 liposomal amphotericin B 65 interferon IFN 65 MGUS 65 nucleotide analog 65 trastuzumab emtansine T DM1 65 mitoxantrone chemotherapy 65 anemia hemoglobin 65 QTcF 65 EGFR mutation status 65 univariate 65 haematological 65 tuberculin skin testing 65 achieved CCyR 65 GnRH antagonist 65 prucalopride 65 experienced virologic failure 65 dopaminergic therapy 65 gastrointestinal stromal tumors GISTs 65 empiric treatment 65 renal toxicity 65 nucleotide analogue 65 salmeterol fluticasone 65 Naive Patients 65 partial remissions 65 mg TID 65 Dasatinib 65 low dose cytarabine 65 oral anticoagulation 65 UGT#A# 65 PROSTVAC VF 65 CHAMPION PCI 65 tirofiban 65 radiographic outcomes 65 anti HBs 65 echocardiographic parameters 65 virologically suppressed 65 prostate carcinoma 65 ascending dose 65 receiving VICTRELIS 65 dexamethasone Decadron 65 HCV RESPOND 2 65 cediranib 65 lamivudine refractory patients 65 lenalidomide Revlimid 65 antiepileptics 65 tamoxifen Nolvadex ® 65 PSMA ADC 65 HIV HCV coinfected 65 severe neutropenia 65 NAbs 65 rHuEPO 65 scintigraphic 64 transaminase elevations 64 urodynamic 64 subgroup analyzes 64 Pegylated Interferon 64 cytogenetic abnormalities 64 progression TTP 64 interferon gamma 1b 64 thiopurine 64 amprenavir 64 decitabine 64 pharmacodynamic PD 64 TEAEs 64 ER CHOP 64 VKORC1 64 DLTs 64 serologic tests 64 temsirolimus 64 Aflibercept 64 histologies 64 mutated K ras 64 corticosteroid therapy 64 genotype 1b 64 favorable pharmacokinetic profile 64 refractory chronic lymphocytic 64 Aptivus ® 64 chest radiographs 64 visilizumab 64 statistically significant p = 64 Aplidin 64 subcutaneous PRO 64 adefovir dipivoxil 64 ORENCIA ® 64 guideline concordant 64 heavily pretreated patients 64 plasma kallikrein inhibitor 64 CIMZIA TM 64 LEXIVA r 64 voriconazole 64 neoadjuvant 64 hematological relapse 64 torezolid 64 achieved statistical significance 64 RezularTM 64 TMP SMX 64 biochemical recurrence 64 treatment naïve genotype 64 daunorubicin 64 normal karyotype 64 HCV antibody 64 ibandronate 64 RAS mutations 64 hepatitis C genotype 64 canakinumab 64 MBq 64 TNFalpha 64 genomic biomarker 64 GSK# [001] 64 thyroglobulin 64 entecavir 64 STRIDE PD 64 antiarrhythmic drug 64 latent tuberculosis infection 64 efalizumab 64 interferon alfa 2a 64 Secondary endpoints 64 clinically evaluable 64 raltegravir 64 potentially hepatotoxic 64 LHRH receptor positive 64 LTBI 64 intracranial hemorrhage ICH 64 recurrent metastatic 64 flavopiridol 64 refractory CLL 64 statistical significance p 64 DermaVir Patch 64 HLA A2 64 genotype 1a 64 serum urate levels 64 immunostaining 64 valganciclovir 64 Panzem R NCD 64 anti JCV antibodies 64 CTAP# Capsules 64 Pemetrexed 64 tolterodine ER 64 hematologic abnormalities 64 EOquin TM 64 maximal doses 64 beta interferons 64 LV dysfunction 64 EDEMA3 trial 64 conditional logistic regression 64 IMiDs ® compound 64 KRAS mutations 64 Stage IIIb 64 null responder HCV 64 alpha 2a 64 adriamycin 64 bortezomib Velcade 64 postprocedure 64 nitazoxanide 64 macroalbuminuria 64 prednisone prednisolone 64 EGFR tyrosine kinase inhibitors 64 investigational protease inhibitor 64 NMDA antagonists 64 interferon alfa 64 immune modulating 64 intravenous bisphosphonates 64 KRAS mutation 64 intact parathyroid hormone 64 sulfasalazine 64 distant metastasis 64 gonococcal 64 mitoxantrone 64 Multivariate analysis 64 arteriography 64 dose regimens 64 #mg QD [002] 64 anthracyclines taxanes 64 immunohistochemical 64 randomized controlled trials RCTs 64 doxorubicin cyclophosphamide 64 chlorambucil 64 prospectively stratified 64 cardiac repolarization 64 RLAI 64 intraobserver 64 immunological responses 64 immunosuppressive regimen 64 anti angiogenic agents 64 NSABP B 64 invasive candidiasis 64 RAPAFLO R 64 cisplatin chemotherapy 64 empiric 64 azacytidine 64 pharmacokinetic characteristics 64 antiretroviral regimen 64 lopinavir r 64 discontinued Viread 64 EGFR HER2 64 Daptomycin 64 hepatocellular carcinomas 64 hip resurfacing arthroplasty 64 somatostatin analog 64 subclinical disease 64 R5 tropic 64 PDE4 inhibitors 64 Virulizin ® 64 urate lowering 64 macrolide antibiotic 64 antibiotic regimens 64 PASI scores 64 TNF antagonist 64 gefitinib Iressa 64 SCIg 64 Pegylated Liposomal Doxorubicin 64 efavirenz Sustiva 64 daptomycin 64 specific antigen PSA 64 peginterferon 64 Femara letrozole 64 replicon 64 viral titers 64 trials RCTs 64 relapsing remitting MS RRMS 64 antiemetics 64 Fludarabine 64 lenalidomide Revlimid R 64 endometrial carcinoma 64 EndoTAGTM 1 64 hypophosphatemia 64 PREZISTA rtv 64 rhGH 64 Teriflunomide 64 novel VDA molecule 64 gemcitabine Gemzar ® 64 idarubicin 64 prognostic variables 64 ximelagatran 64 G CSFs 64 active comparator 64 alfa 2a 64 ABVD 64 acromegalic patients 64 resectable pancreatic cancer 64 denileukin diftitox 64 sunitinib malate 64 factor TNF 64 Protease Inhibitors 64 INVEGA ® 64 CHOP chemotherapy 64 CLL SLL 64 tenofovir emtricitabine 64 serologic testing 64 cefazolin 64 placebo dexamethasone 64 preintervention 64 Akt inhibitor 64 gene loci 64 tumor xenograft models 64 Dacogen decitabine 64 PTPN# 64 Candesartan 64 CLORETAZINE TM VNP#M 64 hematologic parameters 64 visceral metastases 64 TNF blocker therapy 64 d4T 64 myelodysplastic myeloproliferative diseases 64 lipid lowering therapies 64 candidemia 64 nucleoside naive patients 64 alanine aminotransferase ALT 64 QT QTc 64 Index CDAI 64 K#R [002] 64 polytherapy 64 HbA 1c levels 64 nonnucleoside reverse transcriptase inhibitor 64 Renal Cell Carcinoma RCC 64 pT2 64 Tumor Response 64 attain statistical significance 64 Immunohistochemical staining 64 florbetaben 64 logistic regression analysis 64 steroid dexamethasone 64 cytoreductive nephrectomy 64 chronic HBV 64 aspirin clopidogrel 64 Bonferroni correction 64 multivariate Cox 64 pegIFN 64 antithrombotic therapy 64 peginterferon alpha 2a 64 aminotransferase levels 64 NPM1 mutation 64 Randomized trials 64 intravenous dosing 64 recurrent NSCLC 64 H. pylori eradication 63 lymphopenia 63 IFN beta 63 Kaplan Meier curve 63 solithromycin 63 iniparib BSI 63 rFVIIa 63 dexmedetomidine 63 thrombophilia 63 aminotransferases 63 posttransplant 63 chlamydial 63 median survivals 63 multivariate logistic regression 63 serum cortisol 63 microdose 63 acyclovir Lauriad R 63 carotid IMT 63 BRIM3 63 glycated hemoglobin levels 63 PROCHYMAL 63 pretransplant 63 cytogenic 63 oral Hycamtin 63 FUSILEV enhances 63 intestinal metaplasia 63 mycophenolate mofetil MMF 63 dacetuzumab 63 non nucleoside 63 receiving prophylactic anticoagulation 63 MYLOTARG 63 Pharmacodynamic 63 lymphocytosis 63 epoetin alpha 63 lopinavir ritonavir Kaletra 63 venlafaxine XR 63 pegylated IFN 63 MRSA isolates 63 viral kinetic 63 nutlin 3a 63 rifamycin 63 generation antisense inhibitor 63 T2DM 63 clinically meaningful improvement 63 pegylated interferon alfa 2a 63 HGS ETR2 63 ritonavir boosted atazanavir 63 primary aldosteronism 63 radiotherapy RT 63 Surgical resection 63 basal cell carcinoma BCC 63 intravascular hemolysis 63 ATACAND 63 HPV-#/# 63 clinicopathological features 63 chemotherapeutic regimen 63 aflibercept VEGF Trap 63 decompensated cirrhosis 63 ALT elevations 63 dose titration 63 lactate dehydrogenase LDH 63 oblimersen 63 gemtuzumab ozogamicin 63 Tarceva TM 63 Histologic 63 E. faecalis 63 biologic DMARD 63 XIENCE V PROMUS Stent 63 autologous SCT 63 serum PTH 63 antibiotic prophylaxis 63 thorough QT 63 T2 lesions 63 oral ridaforolimus 63 gamma secretase inhibitor 63 invasive carcinomas 63 hMG 63 ADAS Cog 63 virological suppression 63 daily subcutaneous injections 63 transrectal ultrasound guided 63 ARB telmisartan 63 serum antibody 63 AZT 3TC 63 nucleotide substitutions 63 abiraterone acetate 63 metastatic malignant melanoma 63 humoral responses 63 Thalomid ® 63 Vidaza ® 63 antigen PSA levels 63 APOE genotype 63 sitaxsentan 63 thromboembolic complications 63 saquinavir 63 CIN3 63 antiangiogenic agents 63 warfarin anticoagulation 63 thromboprophylaxis 63 Targretin capsules 63 fluticasone salmeterol 63 melphalan prednisone 63 ddI 63 insulin detemir 63 cytostatic 63 XELOX 63 oxaliplatin Eloxatin 63 ruxolitinib 63 hA# 63 fulvestrant 63 demonstrated antitumor activity 63 HER2 positive cancers 63 hemostatic efficacy 63 logistic regression analyzes 63 Meta analyzes 63 oral talactoferrin 63 Phase Ib II 63 extrapyramidal symptoms 63 vinca alkaloid 63 Proellex TM 63 ABC/3TC 63 refractory NSCLC 63 rosuvastatin #mg 63 Hematologic 63 Alequel 63 goserelin 63 SNT MC# 63 hepatoma 63 VNP#M 63 maximally tolerated dose 63 Bcr Abl mutations 63 dasatinib Sprycel ® 63 cerebral vasospasm 63 Copegus ribavirin 63 airway responsiveness 63 quasispecies 63 Viread Emtriva 63 pegylated interferons 63 chlamydial infection 63 fluconazole resistant 63 fluoxetine paroxetine 63 Peginterferon Alfa 2a 63 intermittent dosing 63 antibody MAb 63 Telintra 63 etanercept Enbrel 63 metastatic GIST 63 pegylated interferon alfa 2b 63 advanced adenomas 63 metastatic HRPC 63 adecatumumab 63 pyridostigmine 63 pegylated interferon alpha 63 tolevamer 63 clinically meaningful differences 63 platelet reactivity 63 endometrial hyperplasia 63 μmol L 63 univariate analysis 63 corrected QT interval 63 xenograft models 63 zonisamide SR 63 postoperative AF 63 mcg BID 63 #mg/day [001] 63 indinavir Crixivan 63 Pegylated interferon 63 urine cytology 63 hemorrhagic complications 63 RhuDex ® 63 seroprotection 63 mapatumumab 63 mesalamine granules 63 pegylated alpha interferon 63 metaplasia 63 docetaxel Taxotere ® 63 systemic RNAi therapeutic 63 telaprevir VX 63 relapsed ALL 63 EGFR TKIs 63 standard chemotherapy regimen 63 immunohistochemical analysis 63 aprepitant 63 elevated serum creatinine 63 tumorigenicity 63 CR CRu 63 eplerenone 63 decompensated liver disease 63 LAB CGRP 63 null responder 63 regorafenib 63 prospective multicentre 63 hepatorenal syndrome 63 nodal metastasis 63 serum biomarkers 63 RRM1 63 rilpivirine 63 Bezielle 63 cilostazol 63 peg interferon 63 IOP lowering 63 CCR5 tropic 63 carboplatin paclitaxel 63 smoldering multiple myeloma 63 mTOR inhibitors 63 non squamous NSCLC 63 eribulin mesylate 63 ascending doses 63 elevated transaminases 63 nucleotide analogs 63 sulphonylureas 63 ELACYT 63 YONDELIS 63 neutrophil counts 63 parasitological 63 oral prodrug 63 INFERGEN 63 PREZISTA ritonavir 63 p = NS 63 paroxysmal AF 63 Natalizumab 63 unfractionated heparin UFH 63 gemcitabine cisplatin 63 COMBIVIR 63 HIV uninfected 63 ularitide 63 Poisson regression 63 SSc 63 ABL1 63 histologically confirmed 63 induced sputum 63 zidovudine lamivudine 63 Gleevec resistant 63 UPLYSO 63 warfarin dosage 63 BCG refractory 63 HCV genotypes 63 receptor blocker 63 tamsulosin 63 Leydig cell 63 lymphocyte count 63 G#DT 63 etravirine 63 deep venous thromboses 63 4mg/kg 63 tolterodine 63 5-FU/LV 63 colorectal liver metastases 63 isotype 63 Noxafil 63 phase Ib 63 Haptoglobin 63 APTIVUS ritonavir 63 conventional DMARDs 63 Oral corticosteroids 63 empiric therapy 63 resected pancreatic cancer 63 GnRH agonists 63 PROSTVAC ® 63 mg RDEA# 63 standard chemotherapy regimens 63 systemically administered 63 -#.# ± [002] 63 Elitek 63 chemoradiotherapy 63 cabazitaxel 63 oral rivaroxaban 63 Azacitidine 63 HPV subtypes